Approved for use through 9/30/2007. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

er the Paperwork Reduction Act of 1995, no persons are require

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 3

to respond to a collection of information un	tess it displays a valid OMB control number.
Confirmation Number	3740
Application Number	10/690,115
Filing Date	10-21-2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attomay Docket Number	PRD2033LISNP

		nent			Pages, Columns, Lines, where relevant passages or relevant figures appear
Cite No.1	Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	
	5,756,504	Α	Bock et al.	05-26-1998	
	5,889,006	Α	Lowe et al.	03-30-1999	
	6,596,706	B1	Kikuchi et al.	07-22-2003	Corresponding English equivalent to WO 9924475
		- 1			
	No.1	5,756,504 5,889,006	5,756,504 A 5,889,006 A	No.1   NUTILEEF   (IF RIDWH)	No.1         Number         (in rower)         mm-dd-уууу           5,756,504         A         Bock et al.         05-26-1998           5,889,006         A         Lowe et al.         03-30-1999

## FOREIGN PATENT DOCUMENTS

		Foreign Patent Document		nt	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>d</sup>
Examiner Initials	Cite No.1	Office <sup>3</sup>	fice <sup>3</sup> Number <sup>4</sup> KindCode <sup>5</sup>			mm-dd-yyyy		
		wo	952544 3	A1	Merck & Co., Inc.	09-28-1995		
		wo	962619 6	A2	Schering Corporation	09-29-1995		
		wo	980529 2	A2	Schering Corporation	02-12-1998		
		wo	992447 5	A1	Daiichi Pharmaceutical Co., Ltd.	05-20-1999	See corresponding US Patent 6,596,706	

Examiner	Date	1
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional), 2 See Kinds Codes of U.S. Patent Documents at <a href="https://www.usplo.gov">www.usplo.gov</a>. Seller Office that issued the document, by the two-letter code (WIPO Standard ST.3), 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible, a Applicant is to place a check mark here if English language Translation is attached.

English angingage intrinsation is anticined. This collection of information required to obtain or retain a benefit by the public which is to file (and by the UBPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR.1.4. This collection is electricated to a set invaled to take 2 hours to complete, including appliering, preparing, and submitting the completed application to the USPTO. Time will law depending upon the individual case. Any comments on the amount of the mount of the control of the ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (04-07) Approved for use through 9/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 3

Confirmation Number	3740
Application Number	10/690,115
Filing Date	10-21-2003
First Named Inventor	Richard Apodaca
Group Art Unit	1624
Examiner Name	Brenda Libby Coleman
Attorney Docket Number	PRD2033USNP

	_	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item.	
Examiner's Initials*	Cite No.1	include name of the author (in CAPTIAL LETTENS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, 6c.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		IBRAHIM, EL SEBAI A. et al.: "Synthesis of 4-Substituted Aminobenzoate Quaternary Salts as Potent Antispasmodic Agents"; J. of Pharmaceutical Sciences (1979) 68(3): 332-335.	
		MIOCQUE, MARCEL et al.: "Derivatives of Imipramine: Aminomethylation of Diphenylamine and of Iminodibenzyl"; Eur. J. Med. Chem. – Chimica Therapeutica, (May-June 1977) 12(3): 219-225. Note: Copy of English-language translation is attached.	
	-		

Examiner	Date Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Proposal is under outside tree-glaster insuler by an Explosion / Public and 1.8. In a high public and the publi